David Launay
A5014020914- Systemic Sclerosis and Related Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Pulmonary Hypertension Research and Treatments
- Inflammatory Myopathies and Dermatomyositis
- Systemic Lupus Erythematosus Research
- Mast cells and histamine
- Eosinophilic Disorders and Syndromes
- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Vasculitis and related conditions
- Sarcoidosis and Beryllium Toxicity Research
- Immunodeficiency and Autoimmune Disorders
- Dermatologic Treatments and Research
- Medical Imaging and Pathology Studies
- Skin Diseases and Diabetes
- Salivary Gland Disorders and Functions
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Platelet Disorders and Treatments
- IgG4-Related and Inflammatory Diseases
- Dermatological and Skeletal Disorders
- Hemophilia Treatment and Research
- Eosinophilic Esophagitis
- Blood disorders and treatments
- Vitamin K Research Studies
Lille Inflammation Research International Center
2016-2025
Institute for Translational Research in Inflammation
2020-2025
Inserm
2016-2025
Centre Hospitalier Universitaire de Lille
2016-2025
Université de Lille
2016-2025
Hôpital Nord
2014-2025
Hôpital Claude Huriez
2015-2024
Université Grenoble Alpes
2012-2024
Université Lille Nord de France
2015-2024
Centre Hospitalier Universitaire de Grenoble
2012-2024
Abstract Objective Screening allows for early management of pulmonary arterial hypertension (PAH), a severe complication systemic sclerosis (SSc). Since no consensus has been reached on the method and criteria optimal screening, we sought to develop an algorithm based symptoms, Doppler echocardiography, right heart catheterization (RHC) application nationwide multicenter SSc population in France. Methods This prospective study was conducted from September 2002 July 2003 by experts at 21...
High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis phase 1 small 2 trials.To compare safety of HSCT vs 12 successive monthly intravenous pulses cyclophosphamide.The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a 3, multicenter, randomized (1:1), open-label, parallel-group, clinical trial conducted 10 countries at 29 centers with access to European Group for Blood Marrow...
Abstract Objective To describe the response to first‐line immunosuppressive therapy with or without pulmonary vasodilators in arterial hypertension (PAH) associated systemic lupus erythematosus (SLE) mixed connective tissue disease (MCTD). Methods Twenty‐three consecutive patients SLE‐ MCTD‐associated PAH treated either alone (n = 16) combination 7) were evaluated according clinical and hemodynamic criteria before after therapy. Responders defined as New York Heart Association (NYHA)...
Pulmonary arterial hypertension (PAH) is a severe, life-limiting complication of systemic sclerosis (SSc). Guidelines recommend early detection and management SSc-PAH. However, little known about the impact programs on patients with This study was undertaken to assess clinical characteristics SSc-PAH at diagnosis their long-term outcomes.Two incident cohorts from same era (2002/2003) were studied. The first cohort (designated routine practice cohort) included consecutive adult symptomatic...
Objective. We describe myelodysplastic syndrome (MDS)–associated systemic inflammatory and autoimmune diseases (SIADs), their treatments outcomes the impact of SIADs on overall survival in a French multicentre retrospective study. Methods. In this study, 123 patients with MDS were analysed. Results. Mean age was 70 years (s.d. 13) male:female ratio 2. The vasculitis 39 (32%) cases, CTD 31 (25%) arthritis 28 (23%) neutrophilic disorder 12 (10%) cases unclassified 13 (11%). fulfilled usual...
Abstract The recently described vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by mutations in UBA1. Patients with VEXAS display late-onset autoinflammatory symptoms, usually refractory to treatment, and hematologic abnormalities. identification of an easily-accessible specific marker (UBA1 mutations) particular interest as it allows the convergence various inflammatory hematological symptoms a unique clinico-biological entity gives opportunity design...
To assess the prevalence and patterns of cardiac abnormalities as detected by magnetic resonance imaging (MRI) in systemic sclerosis (SSc).Fifty-two consecutive patients with SSc underwent MRI to determine morphological, functional, perfusion at rest delayed enhancement abnormalities.At least one abnormality on was observed 39/52 (75%). Increased myocardial signal intensity T2 6 (12%), thinning left ventricle (LV) myocardium 15 (29%) pericardial effusion 10 (19%). LV right (RV) ejection...
Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood concentration ([HCQ]) varies widely between patients and a marker predictor of SLE flares. This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml reduce was measured in 573 with (stable disease SELENA-SLEDAI≤12) treated at least 6 months. Patients from 100 750 were...
Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort patients with SSc without severe pulmonary fibrosis or left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from investigators French national records. Causes were classified as SSc-related otherwise. Data censored 37 months, time loss to whichever earlier. Survival estimated using Kaplan–Meier method. Multivariate...
To assess the survival and prognostic factors in patients with newly diagnosed incident systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) modern management era.Prospectively enrolled SSc French PAH Network between January 2006 November 2009, no interstitial lung disease, were analysed (85 patients, mean age 64.9±12.2 years). Median follow-up after diagnosis was 2.32 years.A majority of NYHA functional class III-IV (79%). Overall 90% (95% CI 81% to 95%), 78% 67% 86%)...
Antisynthetase syndrome is characterised by the association of interstitial lung disease and myositis with different anti-tRNA-synthetase antibodies. The occurrence, aetiology prognosis pulmonary hypertension have not yet been evaluated. Among 203 consecutive patients, transthoracic echocardiogram right heart catheterisation results were retrospectively analysed in light clinico-biological, morphological functional parameters. Definitions based on European Society Cardiology/European...
Precapillary pulmonary hypertension (PH) is an important cause of death in patients with systemic sclerosis (SSc). It can occur isolation (pulmonary arterial [PAH]) or association interstitial lung disease (ILD). Importantly, the outcomes and efficacy PAH therapies SSc-related PH complicating ILD (PH-ILD) remain unknown. This study was undertaken to evaluate our experience PH-ILD regard safety this patient cohort.We conducted a retrospective analysis consecutive SSc from 2 large referral...
Systemic sclerosis (SSc) is an orphan disease characterised by autoimmunity, fibrosis of the skin and internal organs, vasculopathy. SSc may be associated with high morbidity mortality. In this narrative review we summarise results a systematic literature research, which was performed as part European Reference Network on Rare Complex Connective Tissue Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines or recommendations. Only in domains ‘Vascular...